Smart treatment strategies for alleviating tauopathy and neuroinflammation to improve clinical outcome in Alzheimer's disease

Drug Discov Today. 2020 Dec;25(12):2110-2129. doi: 10.1016/j.drudis.2020.09.025. Epub 2020 Oct 2.

Abstract

Alzheimer's disease (AD) is a complex neurodegenerative disease leading to progressive loss of memory that mainly affects people above 60 years of age. It is one of the leading causes of deaths in the USA. Given its inherent heterogeneity and a still-incomplete understanding of its pathology, biomarkers, and targets available for therapy, it is a challenge to design an effective therapeutic strategy. Several hypotheses have been proposed to understand the disease and to identify reliable markers and targets for treatments. However, none have resulted in strong support from clinical trials. In this review, we objectively discuss the various therapeutic strategies and mechanistic approaches to improve the current clinical outcome of AD therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Amyloid beta-Peptides / metabolism
  • Animals
  • Drug Therapy, Combination
  • Humans
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Nanotechnology
  • Neuroprotective Agents / therapeutic use*
  • Tauopathies / drug therapy*
  • Tauopathies / metabolism
  • Treatment Outcome
  • tau Proteins / metabolism

Substances

  • Amyloid beta-Peptides
  • Neuroprotective Agents
  • tau Proteins